Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02230696 · ClinicalTrials.gov registry record · Phase 3
Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis
A Phase 3 study, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 951
- Enrollment target
NCT02230696: Completed Phase 3 study, sponsored by Padagis.
NCT02230696 is a Phase 3 study that has completed, run by Padagis. The registered enrollment target is 951 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02230696, a Phase 3 study, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 951 participants
- Enrollment target
Study Summary
To compare safety and efficacy of Perrigo's steroid drug product compared with an FDA approved steroid drug product in the treatment of subjects with seasonal allergic rhinitis.
Primary Outcome
The symptoms included in the reflective Total Nasal Symptom Score (rTNSS) scale are nasal congestion/stuffy nose, nasal discharge/runny nose, sneezing, and itchy nose. Symptoms were scored on a four point scale, 0-3, for each assessment were calculated by totaling these four symptom scores for a maximum score of 12.
Interventions
- DRUG Placebo nasal spray
- DRUG Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 951 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
What the finished NCT02230696 record still lists
NCT02230696 is an interventional study that assigns participants to a tested intervention. The registered 951 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo nasal spray is the first listed.
NCT02230696 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02230696 about?
NCT02230696 is a clinical study titled "Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis". To compare safety and efficacy of Perrigo's steroid drug product compared with an FDA approved steroid drug product in the treatment of subjects with seasonal allergic rhinitis.
What is the current status of trial NCT02230696?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 951 participants. The study started on 2014-08. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02230696?
The interventions under investigation include: Placebo nasal spray (DRUG), Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT02230696?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02230696's enrollment target sits among peer trials
951 333rd of 2000 higher than 1,668 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia